This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Alzheimer Disease
and you are
over 50
years old
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

The study involves repeated doses of LY3303560 given by injection for 25 weeks. The study will examine how safe repeated doses of LY3303560 are, whether they cause side effects in participants with mild cognitive impairment or Alzheimer's Disease, and how LY3303560 is handled by the body and acts in the body. This study will last up to 64 weeks, not including screening. Screening is required within 90 days prior to the start of the study.

Provided treatments

  • Drug: LY3303560 - IV
  • Drug: Placebo - IV
  • Drug: Florbetapir F 18
  • Drug: Flortaucipir F18

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03019536. The sponsor of the trial is Eli Lilly and Company and it is looking for 24 volunteers for the current phase.
Official trial title:
Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease